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OBJECTIVES Goal of this study was to assess the long-term reproducibility of electrophysiologic drug
testing in patients with ventricular tachyarrhythmias (VT/VF).
BACKGROUND Programmed ventricular stimulation (PVS) is still widely used to guide antiarrhythmic
therapy in patients with sustained ventricular tachycardia/fibrillation (VT/VF). Sotalol is
considered as one of the most effective drugs for VT/VF. Because there is no proof of
long-term reproducibility of a successful drug test with sotalol, we investigated the long-term
reproducibility of drug testing with sotalol.
METHODS Thirty patients with VT/VF (age: 57 6 11 years, 20 patients with coronary heart disease, 7
patients with no structural heart disease, 3 with others) and reproducible induction of VT/VF
(28 patients VT, two patients VF) in a baseline PVS, were suppressible with sotalol (mean
dosage 395 6 137 mg) in a subsequent PVS. After a mean follow-up of 13 6 10 months a
PVS was again performed in patients, who had no evidence of progressive cardiac disease,
who did not experience any arrhythmia recurrences or who were drug compliant. Irrespective
of the inducibility after long-term therapy with sotalol, all patients were kept on the initial
sotalol regimen. All 30 patients had a stable cardiac condition, were free of VT/VF
recurrences and were drug compliant.
RESULTS Despite the clinical efficacy of sotalol, in 12 patients (40%) VT/VF could again be induced
after 13 6 10.2 months. Inducibility was independent of age, heart disease, ejection fraction
and follow-up time. During a further follow-up of 22.1 6 10.9 months, five patients
experienced nonfatal VT recurrences independently of the prior inducibility.
CONCLUSIONS This study shows a lacking long-term reproducibility of an initial effective PVS with sotalol.
Despite an uneventful clinical follow-up, late electrophysiologic testing showed a VT/VF
inducibility in a high portion of patients. Hence, electrophysiologic testing performed late
after the initial drug test may no longer be predictive of outcome. (J Am Coll Cardiol 1999;
33:1989–95) © 1999 by the American College of Cardiology
Despite the increasing number cardioverter–defibrillator
implantations, programmed ventricular stimulation (PVS) is
still widely used to guide antiarrhythmic therapy in patients
with sustained ventricular tachycardia/fibrillation (VT/VF).
Accordingly, serial drug testing was crucial for the patient
recruitment in the AVID and MADIT trials (1,2).
Sotalol is considered as one of the front-line antiarrhyth-
mic drugs for the treatment of VT/VF because it turned out
to be superior to various class I agents in the ESVEM trial
(3). The efficacy of sotalol has been shown in many studies
before, which have relied on the guidance by electrophysi-
ologic (EP) testing (4–10). An essential prerequisite for
drug testing is the short- and long-term reproducibility of
the baseline stimulation and of the drug test itself. Although
the immediate reproducibility of VT/VF was described as
fairly reliable (11–13), the day-to-day reproducibility was
subjected to a variability ranging from 56% to 80% (11,14–
16). The long-term reproducibility of VT/VF inducibility
seems even more problematic (17). Hence, the few studies
available reported a high short-term variability in terms of
VT/VF suppression of serial drug tests (18–20). No study
has so far addressed the long-term reproducibility of VT/VF
suppression by antiarrhythmic drugs. Because a high vari-
ability of drug tests means a possible underestimation of the
clinical efficacy of the tested substance, the purpose of this
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study was to assess the long-term reproducibility of initial
successful EP study with sotalol in patients with VT/VF.
All patients had to have a stable underlying heart disease
and had to be free of VT/VF recurrences during the
follow-up. Similar to the “parallel approach,” as suggested
by Brugada and Wellens, irrespective of inducibility in the
EP study after long-term therapy with sotalol, the drug was
continued and patients were further observed for relapses to
establish the clinical significance of the long-term reproduc-
ibility of VT/VF suppression with sotalol (21,22).
METHODS
Study design. Patients with a history of VT/VF and
suppressible VT/VF by sotalol (EP study 1 and 2) were
reinvestigated after follow-up of at least six months (EP
study 3), who were free of VT/VF recurrences and showed
stable cardiac conditions and were drug compliant (Fig. 1).
Regardless of the inducibility in EP study 3, the identical
sotalol regimen was maintained. The incidence of VT/VF
or sudden cardiac death (SCD) was determined during a
further follow-up and set in correlation to the arrhythmia
inducibility in the prior EP study 3.
Patient selection, inclusion and exclusion criteria. From
January 1992 to January 1997, 195 patients with VT/VF
were inducible in a baseline PVS and tested with sotalol in
a subsequent EP study. Seventy-eight consecutive patients
(age 60 6 12 years, 12 women and 66 men) were completely
suppressible. Each patient was worked up, including coro-
nary angiography, left ventriculography, echocardiography
and exercise testing and, if considered necessary, right
ventriculography. The identified heart disease was in 40
patients coronary heart disease, in 4 right ventricular dys-
plasia, in 17 dilated cardiomyopathy and in 1 valvular heart
disease. In 16 patients, no structural heart disease could be
identified. The mean left ventricular ejection fraction of all
sotalol-responders was calculated at 40 6 15%. The ar-
rhythmia history was in 16 patients SCD and in 62
monomorphic VT. Criteria excluding the use of sotalol were
as follows: hemodynamic intolerance, severe renal insuffi-
ciency, symptomatic bradycardia or hypotension, asthma or
chronic obstructive pulmonary disease, atrioventricular con-
duction disturbances or prolonged QT interval. All patients
were reinvestigated after a follow-up of at least six months
if they were drug compliant during the entire follow-up.
Arrhythmia recurrence like aborted SCD, palpitations,
syncope or documented VT, as well as deterioration of the
cardiac status, led to the exclusion of the patient. After the
follow-up period, echocardiography and exercise testing
were repeated and compared with those initially performed.
If the clinical history and the results of the noninvasive tests
were suggestive of a progressive cardiac disease, the patient
was excluded from the study.
The following reasons led to the exclusion of 48 patients
(61%): 13 patients experienced nonfatal VT/VF recurrences
during sotalol therapy, 5 patients died during follow-up (3
due to SCD, 2 due to extracardial diseases), 2 patients
showed nonsustained torsade de pointes tachycardias during
sotalol treatment, 13 patients had a deterioration of the
cardiac disease (necessitating hospital admission in all pa-
tients), 10 patients did not tolerate sotalol therapy, 1 patient
was lost for follow-up and 4 patients did not give informed
consent. Hence, the remaining 30 patients completed the
whole study (see Table 1 for patients characteristics); all of
them were treated with sotalol in a mean dosage of 395 6
137 mg. Drug compliance was assured in 18/30 patients
taking plasma samples at the time of the EP study 3 for
determination of sotalol plasma levels with high perfor-
mance liquid chromatography.
Electrophysiologic study. All EP studies were performed
with patients in the fasting, nonsedated state after they had
given written informed consent. A baseline study was
carried out after all antiarrhythmic drugs had been discon-
Abbreviations and Acronyms
CL 5 cycle length
EP 5 electrophysiologic
ICD 5 implantable cardioverter–defibrillator
PVS 5 programmed ventricular stimulation
SCD 5 sudden cardiac death
VF 5 sustained ventricular fibrillation
VT 5 sustained ventricular tachycardia
Figure 1. Study design. EP 5 electrophysiologic; VT/VF 5
sustained ventricular tachycardia/fibrillation.
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tinued for $5 half-lives, using conventional techniques of
intracardiac recording and stimulation as has been previ-
ously reported (23). The PVS included four basic drive cycle
lengths (CLs) (500, 430, 375 and 330 ms) with up to double
extrastimuli. A third extrastimulus was then delivered at all
four drive CLs. If necessary the protocol was repeated with
a catheter placed in the right ventricular outflow tract and
eventually subsequent orciprenalin infusion. Each extra-
stimulus was delivered at an initial coupling time of 350 ms
(in the case of 330-ms basic drive CL 320 ms), which was
reduced in 10-ms decrements until ventricular refractoriness
occurred or to a coupling time not below 150 ms. The end
point of our protocol was the induction of the clinical
arrhythmia (i.e., reproducible induction of sustained VT in
patients with a history of sustained VT or aborted SCD or
induction of VF in patients with aborted SCD only).
Definitions. Sustained ventricular tachycardia was defined
as ventricular tachycardia that lasted .30 s or was hemo-
dynamically intolerable and needed termination before 30 s.
Ventricular tachycardia was considered nonsustained if it
terminated spontaneously within 30 s. Sustained ventricular
fibrillation was defined as being polymorphic with a cycle
length below 200 ms.
Efficacy criteria of the EP study with sotalol (EP study 2
and 3). After completion of dose titration of oral sotalol
and a minimum of 72 h of administration of the final dose,
EP testing was repeated. The PVS protocol and the end
points were identical to those used at the baseline investi-
gation. In all patients during each test, three extrastimuli
with basic drive CL of 500 ms were utilized, unless VT or
VF was induced with fewer extrastimuli or the VT/VF
induction in the baseline stimulation required three extra-
stimuli with a basic drive CL of 430, 375 or 330 ms. If so,
the protocol was completed by 330S4. Long-term therapy
with sotalol was used in those patients whose VT/VF was
either rendered noninducible or rendered nonsustained. The
latter criterion was only applicable to one patient.
After long-term therapy with sotalol, the same stimula-
tion protocol was performed in each patient using the same
efficacy criteria (EP study 3).
Follow-up. All patients were followed up at three month
intervals up to the EP-study 3. Afterwards the patients were
seen also in three month intervals, after one year follow-up
at yearly intervals in an outpatient clinic. Primary end points
were the occurrence of VT/VF, unexplained syncope, SCD
or discontinuation of sotalol. In patients with VT/VF
relapses after EP-study 3 the same non-invasive tests were
performed as before.
Data analysis. All values are expressed as mean 61 stan-
dard deviation. Univariate analysis was performed with the
non-paired two-tailed t test. Group comparison was done
by using Fisher’s exact test or the chi-square test where
appropriate. A p value , 0.05 was considered statistically
significant. Kaplan-Meier survival analysis with the log-
rank test was used to report the estimates for the occurrence
of study end points during follow up.
RESULTS
Baseline EP-study and subsequent EP-study with sotalol
(EP study 1 & 2). As required for the inclusion into the
study, in all 30 patients VT/VF could be induced. In
patients with aborted SCD a monomorphic VT was in-
duced with 2 extrastimuli in 4 patients and with 1 extra-
stimulus in 1 patient with a mean CL of 225 ms 6 25 ms.
In the other 2 patients with SCD, VF was induced utilizing
2 and 3 extrastimuli, respectively. The remaining patients
with a history of VT showed a reproducible induction of
monomorphic VT utilizing 1 extrastimulus in 4, 2 extra-
stimuli in 13 and 3 extrastimuli in 6 patients. The mean CL
of the induced VT was 310 6 45 ms. For VT induction
stimulation with 2 extrastimuli at the right ventricular
outflow tract during orciprenalin infusion was required in 2
patients (1 without structural heart disease, one with dilated
Table 1. Patient Characteristics and VT/VF Inducibility After Long-Term Sotalol Therapy
Noninducibility of
VT/VF (n 5 18)
Reinducibility of
VT/VF (n 5 12) p Value
Age (yr) 55.8 6 2.8 59.4 6 2.7 0.39
Cardiac disease CAD 5 10 patients CAD 5 10 patients 0.19*
RV dysplasia 5 1 patient RV dysplasia 5 1 patient
Idiopathic 5 5 patients Idiopathic 5 1 patient
DCM 5 2 patients
Primary arrhythmia VT 5 15 patients VT 5 8 patients 0.39
VF 5 3 patients VF 5 4 patients
EF (%) 48.7 6 3.7 42.9 6 3.9 0.3
Sotalol dosage (mg) 364 6 32 440 6 40 0.14
Follow-up (mo) 13 6 9.5 13 6 10.2 0.98
(median 6.5) (median 6.5)
*p was calculated for comparison of CAD patients.
CAD 5 coronary artery disease; DCM 5 dilative cardiomyopathy; EF 5 ejection fraction; RV 5 right ventricular; VT/VF 5
sustained ventricular tachycardia/fibrillation.
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cardiomyopathy). In all but one patient sotalol (mean dose
of 395 6 137 mg) prevented completely the induction of
VT/VF in the subsequent drug test. In one patient, ventric-
ular tachycardia was rendered more difficult to induce and
was nonsustained.
Status of underlying heart disease. After a mean
follow-up of 13 6 10 months (median 6.5 months, range 6
to 36 months) all 30 patients were readmitted for electro-
physiologic reevaluation. All patients denied new symptoms
such as angina pectoris, dyspnea and palpitations which
would have been suggestive of a progress of the cardiac
disease or for arrhythmia recurrence. Exercise tests and
echocardiography were performed and compared with the
tests performed during the prior hospital stay. A significant
reduction in left ventricular function or exercise capacity was
not found in any of the patients.
Drug compliance and sotalol plasma levels. Sotalol
plasma levels were taken at the beginning of the PVS
(before 12:00 AM) and were available in 18 patients. The
mean plasma level was determined with 2.2 6 1.5 mg/ml
(therapeutic range: 1 to 3 mg/ml); all patients showed
plasma levels within the therapeutic range. The local phy-
sicians and the follow-up outpatient visits assured drug
compliance in all remaining patients.
Electrophysiologic study during long-term sotalol ther-
apy (EP study 3). After 13 6 9.5 months (median 6.5
months, range 6 to 36 months) of sotalol therapy in 18
patients again no VT/VF was inducible in the EP study 3.
However in the remaining 12 patients (40%) VT/VF could
again be induced despite an uneventful follow-up of 13 6
10.2 months (median 6.5 months, range 6 to 31 months). In
four patients the induced VT differed in morphology: three
VTs were different in QRS axis and one VT was polymor-
phic. In one patient with SCD and VF in the baseline
stimulation again VF was inducible despite complete sup-
pression in the initial drug study with sotalol. As outlined in
Table 1, the two groups of reinducible and noninducible
patients did not differ significantly with respect to age, heart
disease, follow-up time or ejection fraction. The sotalol
dosage tended to be higher with 440 6 138 mg as compared
with 364 6 132 mg in the group with reinducible VT/VF
but without reaching statistical significance. Regarding the
primary arrhythmia, there were more patients with aborted
SCD among the group with reinducible VT/VF (p 5 0.39).
However all patients of this group had reproducible VT in
the baseline EP study 1. The extrastimuli required for
reinduction as compared with the extrastimuli utilized in
the baseline stimulation are illustrated in Table 2. As
illustrated, a total of seven patients required more extra-
stimuli in the EP study 3 as compared with the EP study 1.
Five patients required fewer or the same number of extra-
stimuli to induce VT/VF as compared with the initial study.
Follow-up after EP study 3 during long-term sotalol
therapy. After the EP study 3, all patients continued the
treatment with sotalol and were further followed for 22.1 6
10.9 months (median 22.5, range 2 to 37 months). Three
patients with reinducible arrhythmias wanted cardioverter–
defibrillator implantation, which was subsequently per-
formed. All these patients remained without discharges
from the devices.
Five patients (17%) experienced documented monomor-
phic VT recurrences during the follow-up period. Nonin-
vasive tests did not reveal any progress of the underlying
cardiac disease. Among this group, four patients were again
noninducible; one was reinducible in the EP study 3. All
other 25 patients remained free of arrhythmia recurrences;
no SCD occurred. As illustrated by Figure 2, survival free
from recurrent VT did not differ significantly between the
two groups.
Table 2. Number of Extrastimuli Required to Induce VT/VF in the Baseline EP Study 1 and After Long-Term Sotalol Therapy
(EP Study 3)
EP Study 3
Baseline EP Study 1
500S2 500S2S3 430S2 430S2S3 375S2S3 330S2S3 500S4
500S2 Less difficult to induce VT/VF





330S2S3 More difficult to induce VT/VF




*The same number of extrastimuli was required to induce VT/VF in the baseline EP study and in the late EP study 3. The numbers in the table correspond to the number of
patients who had inducible arrhythmias in response to the programmed stimulation sequence shown. For example, one patient, shown in the first column of the table, had
inducible VT/VF in response to a single extrastimulus during a drive train of 500 ms during baseline EP testing, but required two extrastimuli during late EP retesting while
treated with sotalol.
EP 5 electrophysiologic; VT/VF 5 sustained ventricular tachycardia/fibrillation.
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DISCUSSION
Main findings. The purpose of this study was to prove the
long-term reproducibility of VT/VF suppression by sotalol
in electrophysiologic testing. Of 30 patients, who were all
treated clinically efficiently by sotalol, 40% were reinducible
in a PVS which was performed 13 6 10 months after the
initial successful drug test. The further outcome of the
patients did not differ in terms of VT recurrences, although
all patients were kept on sotalol irrespective of the induc-
ibility in EP study 3. This study shows clearly the lack of
long-term reproducibility of drug testing with sotalol and
the minor clinical significance of inducibility or noninduc-
ibility in late EP testing under sotalol, which is clinically
effective during long-term treatment.
The analysis of the outcome of all screened 78 patients
resulted in a high VT/VF recurrence rate of 27% despite the
fact that all patients were initially suppressible by sotalol.
Reproducibility of serial drug testing. Our study results
are in agreement with some studies that have shown a high
variability of short-term reproducibility of drug trials; Ku-
denchuk et al. (18) found a day-to-day variability of nearly
23% of initially successful drug studies in patients with
coronary artery disease. In 18% of patients with VT/VF
unrelated to coronary artery disease, VT/VF could again be
induced in a second study 48 h after an initial effective study
(19). Fogoros et al. demonstrated that even in 62% of
initially successful drugs VT was inducible in repeat trials
(20). The authors performed the identical stimulation pro-
tocol six times with the initially successful drug at 2 days. It
was concluded that inducibility of VT/VF appeared to be a
probability function, which had already been confirmed
before by Cooper et al., who showed an increase of the
sensitivity of arrhythmia induction during baseline testing
with simple repetition of extrastimuli (24).
Temporal variability of the arrhythmogenic substrate?
The proved high temporal variability of responses on PVS
(14,16,17) could be explained by the fact that arrhythmias
induced by PVS might define at best the arrhythmogenic
potential of a given substrate at the time the test is
performed (25). Because the arrhythmogenic substrate is
subject to a wide variety of pathophysiologic changes, drug
effectiveness predicted by PVS might change with time. We
tried to exclude any instability of the arrhythmogenic
substrate in our patients, performing noninvasive tests and
relying on the clinical history of the patient, which both
suggested a stable clinical disease. Most of our patients
presented a presumably stable substrate with a history of
coronary heart disease and old myocardial infarctions; how-
ever, six patients did not have any structural heart disease
with a less stable arrhythmogenic substrate. In these patients
VT, was harder to induce than in others, which might have
an influence on the reproducibility of arrhythmia induction
in later drug tests (15). However, these patients did not
differ significantly with respect to the reinducibility in the
later EP study compared with the patients with underlying
heart disease.
The reinducibility of VT/VF in our patients who were
clinically effectively treated with sotalol did not have any
prognostic impact. This discrepancy may be explained by
the fact that PVS is a completely unphysiologic test with
characteristics like stimulus strengths and short coupling of
extrastimuli, which cannot be individually matched with the
patient’s substrate to ensure that an elicited response is
always clinically relevant (26). Results of PVS may therefore
underestimate the real clinical efficacy of sotalol, as shown
by our study, because the true positive or false positive test
results cannot be recognized by the response to PVS.
Trials using electrophysiologic guidance of sotalol ther-
apy. The fact that the arrhythmia recurrence rate in the first
year in the ESVEM trial was as high as 21% to 44% for
sotalol and class I agents suggests a relatively weak predic-
tive accuracy for PVS (3). Also, other trials that tested the
long-term efficacy of sotalol guided by PVS reported a high
relapse rate of sotalol despite complete suppression during
serial drug testing, which is also confirmed by the high
relapse rate of all our screened patients primarily effectively
treated with sotalol (4,27,28). Recently Haverkamp et al.
reported that despite the fact that suppression of inducibility
of VT/VF by sotalol predicted a favorable outcome, PVS
failed to predict freedom from SCD during long-term
sotalol therapy (9). Also, Brugada et al. found that the
clinical efficacy of a drug did not necessarily correspond to
the results of serial drug testing (21,22). A small trial
reported that the outcome of patients treated with sotalol
for VT/VF was independent of inducibility in terms of
nonfatal VT recurrences (29). Recently we reported the
long-term outcome of 146 consecutive patients with induc-
ible VT/VF (30). Ninety-nine patients with inducible
VT/VF during sotalol treatment received an implantable
cardioverter–defibrillator (ICD) and then were randomly
assigned to therapy with sotalol or to no antiarrhythmic
therapy. In the remaining 53 patients, sotalol prevented
Figure 2. Curve comparison of patients with sustained ventricular
tachycardia (VT) recurrences: patients with again inducible VT in
electrophysiologic study 3 versus patients with noninducible VT.
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induction of VT/VF and patients were discharged on oral
sotalol. After a follow-up of approximately 33 months, the
groups treated with sotalol alone or with ICD/sotalol
experienced significantly less VT recurrences, with 23% and
30% respectively, compared with 51% in the ICD alone
group. The recurrence rate between the sotalol and ICD/
sotalol groups was not significantly different, although
sotalol did not prevent the induction of VT/VF in the latter
group (30). Furthermore, the recurrence rate of patients
treated with ICD/sotalol is comparable to studies in which
sotalol was only given in the case of complete VT/VF
suppression (4,27,28).
The ESVEM trial. In the ESVEM trial, sotalol was more
effective during follow-up than various class I antiarrhyth-
mic drugs, although EP testing and Holter monitoring
would have predicted similar efficacy (2,31). This suggests
that it was the properties of sotalol that were responsible for
this difference, rather than the techniques by which sotalol
was selected for long-term therapy (25). The ESVEM trial
and the results of our study stress the significance of
drug-specific responses rather than a technique specificity of
responses for the treatment of VT/VF (26). Therefore PVS
contains various shortcomings regarding the guidance of the
therapy with sotalol, a complex substance exerting class III
and beta-adrenergic blocking effects (32).
In summary, we showed that in 40% of patients with a
stable cardiac disease and without arrhythmia recurrences
during long-term sotalol therapy, it was possible to reinduce
VT/VF. Seventeen percent of all patients experienced non-
fatal VT recurrences during the further follow-up period of
22 6 11 months. This was independent of VT/VF induc-
ibility in the EP study 3. Thus the reinducibility of VT/VF
during effective long-term treatment with sotalol did not
have any prognostic impact in terms of arrhythmia recur-
rences as compared with that in patients whose VT/VF
could be again completely suppressed.
Study limitations. We decided to use stringent efficacy
criteria for the drug test, using three extrastimuli in all
patients regardless of the mode of induction in the baseline
state, because Beckman et al. showed a significant day-to-
day variability in the number of extrastimuli required for VT
induction (11). We wanted to limit eventual false positive
results of the drug test (33), but we had to expect a higher
rate of VT/VF reinduction in the follow-up EP study using
three extrastimuli in all patients. In concordance, there was
a tendency toward the requirement of more extrastimuli to
reinduce VT/VF after long-term sotalol treatment as com-
pared with the number of extrastimuli required to induce
VT/VF in the baseline EP study. However, this difference
did not reach statistical significance.
To determine the value of PVS in guiding therapy with
sotalol in patients with VT/VF, a different study design
would have been more adequate; patients with suppressible
and nonsuppressible VT/VF should have been included into
the study and late EP testing should have been performed in
all patients including patients with VT/VF recurrences
during the study period. This kind of study protocol would
have necessitated an ICD as backup for ethical reasons.
However, at the time the study protocol was designed, the
therapy guidelines of VT/VF were different from the
guidelines used nowadays.
Conclusions. This study shows that there is discordance
between immediate and late EP testing during sotalol
therapy. Despite an uneventful clinical follow-up in terms of
VT/VF recurrences, late EP testing showed a VT/VF
inducibility in a high proportion of patients. Hence, EP
testing performed late after the initial drug test may no
longer be predictive of outcome.
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